Author: ETEA MCQS.COM

No category found.

  • To proceed with the trial as is.
  • To urgently recommend revising or replacing the outcome measure to ensure reliable and valid data collection, crucial for the integrity of the results.
  • To ignore measurement issues.
  • To tell the clinicians to be more careful.
  • To immediately abandon the therapy.
  • To urgently consider the implications of low power (high risk of Type II error) and the need for a larger, adequately powered trial before discarding a potentially beneficial therapy.
  • To fund a smaller, less expensive trial.
  • To rely solely on the current non-significant p-value.
Scroll to Top